Skip to main content
logo
Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
34.15
+0.65 (1.94%)
At close: Feb 11, 2026

TPEX:7427 Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-87.75-104.92-61-67.13-35.86-31.27
Depreciation & Amortization
7.676.94.281.761.440.98
Other Amortization
0.050.040.070.060.060.06
Loss (Gain) From Sale of Assets
---0.12---
Asset Writedown & Restructuring Costs
-----2.57
Stock-Based Compensation
8.4814.9711.294.913.661.21
Other Operating Activities
0.110.130.09-0.01-0.03-
Change in Accounts Receivable
0.12-0.62-0.09--0.040.09
Change in Inventory
0.23.15-6.16--0.02
Change in Accounts Payable
-0.36.611.05---
Change in Other Net Operating Assets
-8.14-3.09-4.4-16.76-3.15-15.54
Operating Cash Flow
-79.56-76.85-54.99-77.17-33.92-41.88
Capital Expenditures
-0.1-2.11-2.93-0.05-0.04-0.02
Sale of Property, Plant & Equipment
--0.12---
Sale (Purchase) of Intangibles
-1.08-1.36-16.29-1.18-27.97-13.05
Investment in Securities
-45-130.7-160.5-74.19-62.3213.5
Other Investing Activities
-0.120.68-3.18-2.45--
Investing Cash Flow
-46.29-133.49-182.78-77.85-90.320.43
Long-Term Debt Repaid
--3-1.25---
Net Debt Issued (Repaid)
-3-3-1.25---
Issuance of Common Stock
2.22188.84307.49203.3112083.6
Financing Cash Flow
-30.75185.84306.24203.3112083.6
Net Cash Flow
-156.61-24.4968.4748.29-4.2442.15
Free Cash Flow
-79.66-78.96-57.92-77.21-33.96-41.9
Free Cash Flow Margin
-4472.71%-4685.82%-1194.21%-14298.70%-5389.68%-
Free Cash Flow Per Share
-1.83-1.92-1.60-3.20-1.61-2.65
Cash Interest Paid
-----0.02
Levered Free Cash Flow
-55.65-53.21-48.79-50.61-29.53-39.85
Unlevered Free Cash Flow
-55.57-53.14-48.73-50.61-29.53-39.84
Change in Working Capital
-8.126.04-9.6-16.76-3.19-15.43
Source: S&P Global Market Intelligence. Standard template. Financial Sources.